Search global stocks & ETFs...Ctrl K

Learn Mode

BIIB - Biogen Inc

74

$199.36

$1.41 (0.712%)

At market close

$199.56

$0.20 (0.098%)

After Hours 5/12/26, 10:52 PM

Score

3.41/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

BIIB

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$29.43B

Industry

Biotechnology

EPS (TTM)

$9.24

P/E (TTM)

21.45

Div & Yield

FCF Payout Ratio

P/S (TTM)

2.96

P/B

1.58

Diluted Shares

148.40M

Ex-Dividend

Next Earnings

07-29

Forward P/E

13.46

Payout Ratio

P/FCF (TTM)

12.44

FCF Yield

8.04%

Earnings Yield

4.66%

52 Week Range

Score Card

Explore Scores Tab

3.41

Good

Biogen Inc has grown revenue at 1.23% over the past year, which suggests sales are increasing. Also, it has more cash than current liabilities meaning it has enough cash to handle all its debts within the next year, if it wanted to.

Valuation Model

Key Score

4.00

Good

Management

4.00

Good

Growth

3.00

Average

Profitability

2.00

Bad

Fin. Health

1.00

Very Bad

Dividends

Analyst

3.00

Average

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

2 new filings were in the last 7 days

Filter Form Types

Form SC TO-T/A

Unknown Form Type

Filed on 2026-05-06 16:37:48

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-05-06 11:00:55

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-05 16:11:57

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-04-29 17:00:47

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-04-29 06:40:54

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-29 06:05:42

Form ARS

Unknown Form Type

Filed on 2026-04-28 16:47:09

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-28 16:42:53

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-28 16:34:27

Form SC TO-T

Unknown Form Type

Filed on 2026-04-14 07:02:46

Form SC TO-C

Unknown Form Type

Filed on 2026-04-07 17:05:17

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-04-06 18:11:26

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$288.75

44.8%

Avg:

$218.63

9.7%

Low:

$151.50

-24.0%

(% change is relative to the current stock price: $199.36)

Analyst Recommendations

Go to Analyst Tab

3.74

Good

21%

Strong Buy (9)

35%

Buy (15)

42%

Hold (18)

Sell (1)

Strong Sell (0)

About

Website
https://www.biogen.com/
Address
225 Binney Street, Cambridge MASSACHUSETTS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=875045

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

IPO Date

1991-09-17

Industry

Biotechnology

Total Employees

7,500

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

BIIB - Biogen Inc

74

$199.36

$1.41 (0.712%)

$199.56

$0.20 (0.098%)

3.41/5

Stock Unlock

Stock Profile

Score Card

Good

Insider Transactions

Market News

Form SC TO-T/A

Filed on 2026-05-06 16:37:48

Form SCHEDULE 13G/A

Filed on 2026-05-06 11:00:55

Form 4

Filed on 2026-05-05 16:11:57

Form SCHEDULE 13G

Filed on 2026-04-29 17:00:47

Form 10-Q

Filed on 2026-04-29 06:40:54

Form 8-K

Filed on 2026-04-29 06:05:42

Form ARS

Filed on 2026-04-28 16:47:09

Form DEFA14A

Filed on 2026-04-28 16:42:53

Form DEF 14A

Filed on 2026-04-28 16:34:27

Form SC TO-T

Filed on 2026-04-14 07:02:46

Form SC TO-C

Filed on 2026-04-07 17:05:17

Form 3

Filed on 2026-04-06 18:11:26

Financials

Price Targets

44.8%

9.7%

-24.0%

Analyst Recommendations

About

Similar Stocks